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Introduction: The intensity of 18F-fluorodeoxyglucose (18F-FDG)
uptake in positron emission tomography could be of prognostic
significance for patients with non-small cell lung cancer (NSCLC).
The aim of this retrospective study was to evaluate the prognostic
value of the FDG uptake in patients with resected pathologic stage
I NSCLC according to histologic types of the tumors.
Methods: For each patient, a maximum standardized uptake value
(SUVmax) and a partial volume corrected (PVC) SUVmax were
calculated for the primary lesion on positron emission tomography.
To find optimal cutoff values for cancer recurrences, receiver oper-
ating characteristic curves were used.
Results: Among 145 study patients, the mean values of SUVmax
were 7.7 in those with adenocarcinoma (n  70) and 16.0 in those
with other histologies (n 75; p 0.001). Furthermore, the optimal
cutoff values of SUVmax to predict cancer recurrences were iden-
tified as 5.2 in patients with adenocarcinoma and 13.8 in those with
other histologies. In whole patients with pathologic stage I NSCLC,
SUVmax (p  0.025), PVC SUVmax (p  0.014), tumor size (p 
0.048), and weight loss (p  0.041) were significantly associated
with disease-free survival (DFS). Moreover, PVC SUVmax (p 
0.034) and SUVmax (p  0.012) were significantly associated with
DFS in the multivariate analyses.
Conclusions: The intensity of FDG uptake for the primary tumor
was an independent prognostic factor for DFS in whole patients with
pathologic stage I NSCLC. However, caution is needed for the
interpretation of optimal cutoff values of SUVmax according to
tumor histologies.
Key Words: Non-small cell lung cancer, Histology, Positron emis-
sion tomography, Standardized uptake value, Prognosis.
(J Thorac Oncol. 2009;4: 1331–1336)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer-related death for both men and women world-
wide.1 Most patients present with advanced disease, and the
overall 5-year survival rate is only 12 to 15%.1 Although the
prognosis for patients with NSCLC depends on the tumor-
node-metastasis stage, each pathologic stage consists of a
heterogeneous population containing individuals with differ-
ent risks of recurrence and death. NSCLC is a heterogeneous
disease category that comprises at least three distinct types
of lung cancer, namely squamous cell carcinoma, adeno-
carcinoma, and large cell carcinoma. The biologic behav-
ior of the tumor could be related to the histologic type,
which has been identified as an important prognostic factor
for NSCLC patients.2
The 18F-fluorodeoxyglucose (18F-FDG) uptake on
positron emission tomography (PET) has been used for the
diagnosis and staging of lung cancer. Previous studies have
shown that the pretherapeutic 18F-FDG uptake for the
tumor can provide prognostic information.3–5 However, the
prognostic value of 18F-FDG uptake in stage I NSCLC
patients is not well known.
It can be hypothesized that the more metabolically
active the tumor, the worse the outcome. Previous studies
showed that the 18F-FDG uptake of the tumor was signifi-
cantly higher in squamous cell carcinoma than in adenocar-
cinoma.6–8 We investigated whether there are differences in
the optimal cutoff values of 18F-FDG uptake to predict cancer
recurrences in relation to histologic types of the tumors. We
also evaluated the prognostic value of the 18F-FDG uptake in
pathologic stage I NSCLC patients, while correcting for
partial volume effects.
METHODS
Patients
This is a retrospective review of a prospective database.
Between July 2003 and December 2004, a total of 322
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patients with NSCLC underwent surgical resection at Sam-
sung Medical Center (Seoul, South Korea), and 205 patients
had pathologic stage I NSCLC. All patients underwent an
extensive workup, including contrast-enhanced computed to-
mography (CT) scan of the chest and upper abdomen, mag-
netic resonance imaging of the brain, and plain radiograph or
bone scintigraphy if indicated. We reviewed the patient
characteristics, histologic type, histologic grade of differen-
tiation, tumor size (maximal tumor diameter as determined by
the pathologic findings), angiolymphatic invasion on the
surgical specimens, type of surgery, weight loss, and smoking
history. We included patients who met the following criteria:
(1) pathologic stage I NSCLC (excluding bronchioloalveolar
carcinoma or carcinoid tumor); (2) curative resection with
mediastinoscopic lymph node examination or mediastinal
lymph node dissection; (3) 18F-FDG PET within 28 days
before definitive resection; (4) no previous treatment for lung
cancer; (5) no treatment for another malignancy within the 6
months before the diagnosis of NSCLC; (6) 3 months or
longer follow-up data after surgery; (7) survival of the post-
operative period; (8) not receiving postoperative chemother-
apy or radiation therapy; and (9) tumor measuring more than
or equal to 1 cm in its greatest dimension, because the spatial
resolution of the PET scanner is 0.7 to 0.8 cm.9
This review was approved by the Institutional Review
Board of the Samsung Medical Center, which waived the
requirement for informed consent of the individual patients
because of the retrospective nature of the study.
Integrated 18F-FDG PET/CT Acquisition
and Data Analysis
After the patients fasted for at least 6 hours before their
PET/CT examinations, they received an intravenous injection
of 370 MBq of 18F-FDG and then rested for 45 minutes
(43–47 minutes) before undergoing imaging. Image acquisi-
tion was performed using an integrated PET/CT device (Dis-
covery LS; GE Healthcare, Milwaukee, WI) that consisted of
an Advance NXi PET scanner and an 8-slice Light Speed
Plus CT scanner. The 18F-FDG PET data were evaluated
using the maximum standardized uptake value (SUVmax).
We used the region of interest analysis tools included with the
scanner to calculate the SUVmax over the primary tumor
after correction for the injected dose of 18F-FDG and the
patient’s weight. The partial volume corrected SUVmax
(PVC SUVmax) was also evaluated for each primary tumor
as previously described.10,11
Follow-up Evaluation
All the patients who underwent lung resection were
followed up from the day of surgery. Recurrence was defined
as any unequivocal occurrence of new cancer foci in a
disease-free patient. The site of the first cancer recurrence and
the time interval between the surgery and cancer recurrence
were determined. The duration of disease-free survival (DFS)
was calculated as the time interval between the surgery date
and date of the first confirmation of cancer recurrence, death
without evidence of recurrence, or the last clinical contact
attesting to a disease-free status. The follow-up was com-
pleted by December 31, 2008.
Statistical Analysis
The data are presented as number (%) or median
(range) unless otherwise stated. To compare the SUVs ac-
cording to the clinical characteristics, we performed indepen-
dent sample t tests, Mann-Whitney U tests, or Kruskal-Wallis
tests. Receiver operating characteristic (ROC) curves of the
SUVmax and PVC SUVmax for the prediction of recurrence
were generated to determine the cutoff value that yielded the
optimal sensitivity and specificity. The patient population
was subdivided using the cutoff values of SUVmax and PVC
SUVmax from the ROC curves, and the duration of DFS was
analyzed using the Kaplan-Meier method. The differences in
DFS were assessed using the log-rank test. To assess the
potential independent effects of SUVmax (model 1) and PVC
SUVmax (model 2) on DFS, we performed multivariate
analyses using Cox proportional hazard model with the vari-
ables that had a p value less than 0.10 on the univariate
analyses, and p values less than 0.05 were considered to be
statistically significant. Statistical analyses were performed
using SPSS for Windows Release 12.0 (SPSS; Chicago, IL).
RESULTS
Patients
Of the 205 patients with stage I NSCLC, 145 patients
met the inclusion criteria. The reasons for exclusion were as
follows: bronchioloalveolar carcinoma for 15 patients, carci-
noid tumor for 3 patients, not performing PET imaging before
surgery for 23 patients, receiving postoperative chemother-
apy or radiation therapy for 8 patients, treatment for another
malignancy within the 6 months before the diagnosis of
NSCLC for 4 patients, a noncurative resection for 3 patients,
a tumor size less than 1 cm for 2 patients, immediate post-
operative mortality for 1 patient, and a postoperative fol-
low-up duration less than 3 months for 1 patient. The char-
acteristics of the 145 study patients are summarized in Table
1. The median follow-up period after surgery was 51 months
(5–64 months). During the follow-up period, 43 patients
(29.7%) had disease recurrence, which was confirmed by the
histopathology (n 17) or the imaging studies (n  26). The
median interval between surgery and recurrence was 16
months (3–52 months). During the follow-up period, nine
patients died of relapsed lung cancer, and three patients died
of other causes.
SUVmax and Cancer Recurrence according to
Tumor Histology
The mean values of SUVmax and PVC SUVmax were
significantly lower in patients with adenocarcinoma than in
those with other histologies (Table 2). Furthermore, the
SUVmax for the primary tumor was significantly associated
with the stage, tumor size, and histologic grade of differen-
tiation (Table 2). The PVC SUVmax for the primary tumor
was also significantly associated with the histologic grade of
differentiation (Table 2).
The ROC curve showed that the optimal cutoff values
of SUVmax and PVC SUVmax for predicting cancer recur-
rence were 13.1 (an area under curve [AUC] of 0.704) and 8.0
(an AUC of 0.703) in whole population, respectively. Be-
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cause there was a significant difference in the mean SUVmax
and PVC SUVmax in relation to the histology of the tumor,
we calculated the optimal cutoff values of SUVmax and PVC
SUVmax in relation to the tumor histology. In patients with
adenocarcinoma, the optimal cutoff values of SUVmax and
PVC SUVmax for predicting cancer recurrence were identi-
fied to be 5.2 (an AUC of 0.756) and 4.5 (an AUC of 0.764),
respectively. In patients with other histologies, the optimal
cutoff values of SUVmax and PVC SUVmax were identified
to be 13.8 (an AUC of 0.717) and 14.8 (an AUC of 0.722),
respectively. Therefore, the cutoff values of SUVmax and
PVC SUVmax were lower in patients with adenocarcinoma
than in those with other histologies.
Univariate Survival Analysis in Relation to
SUVmax and PVC SUVmax
In 145 study patients, the mean DFS duration was 50.1
months, and the 3-year DFS rate was 74.5%, although the
median DFS has not yet been reached (Table 3). As shown in
Figure 1A and Table 3, there was a significant difference in
TABLE 1. Characteristics of 145 Study Patients
Characteristics
N (%) or Median
(Range)
Age (yr) 63 (38–83)
Male/female 109 (75.2)/6 (24.8)
Smoker/nonsmoker 95 (65.5)/50 (34.5)
Weight loss 10% 14 (9.7)
Pathologic stage
IA 50 (34.5)
IB 95 (65.5)
Histology
Adenocarcinoma 70 (48.3)
Squamous cell carcinoma 63 (43.4)
Large cell neuroendocrine carcinoma 5 (3.4)
Large cell carcinoma 3 (2.1)
Others 4 (2.8)
Histologic grade of differentiation
Well 20 (13.8)
Moderately 91 (62.8)
Poorly 24 (16.6)
Not available 10 (6.9)
Longest tumor dimension, cm 3.0 (1.0–11.0)
Angiolymphatic invasion
No 137 (94.5)
Yes 8 (5.5)
Time interval between PET imaging and
surgery, (d)
5 (1–24)
SUVmax 11.6 (0.5–43.4)
PVC SUVmax 12.3 (0.5–108.2)
Type of surgery
Lobectomy 135 (93.1)
Bilobecomy 8 (5.5)
Pneumonectomy 1 (0.7)
Wedge resection 1 (0.7)
PET, positron emission tomography; SUVmax, maximum standardized uptake
value; PVC SUVmax, partial volume corrected SUVmax.
TABLE 2. Comparison of SUVmax and PVC SUVmax
According to Patient Characteristics
SUVmax p
PVC
SUVmax p
Pathologic stage 0.001 0.240
IA (n  50) 8.9  6.0 12.0  15.0
IB (n  95) 13.6  7.6 15.3  8.3
Tumor size 0.001 0.080
3 cm (n  79) 9.3  6.0 12.0  13.0
3 cm (n  66) 15.2  7.8 15.2  7.8
Histology 0.001 0.001
Adenocarcinoma
(n 70)
7.7  4.7 8.6  5.0
Others (n  75) 16.0  7.4 18.0  13.0
Histologic grade of
differentiation
0.001 0.009
Well (n  20) 5.8  4.8 6.4  4.9
Moderately (n  91) 13.1  8.0 14.8  12.9
Poorly (n  24) 13.6  4.1 14.6  4.1
Not available (n  10) 10.8  6.7 12.8  6.9
Angiolymphatic invasion 0.548 0.575
No (n  137) 11.9  7.6 13.3  11.2
Yes (n  8) 13.6  5.7 15.6  6.5
Data are presented as mean  SD.
SUVmax, maximum standardized uptake value; PVC SUVmax, partial volume
corrected SUVmax.
TABLE 3. Univariate Analysis of the Disease-Free Survival
according to Tumor Histology and FDG Uptake
Factor
No.
Patients
Disease-Free Survival
Mean
Survival (mo)
3-yr
Survival (%)
Log-rank
p
All histologies 145 50.1 74.5
SUVmax 0.025
13.1 86 53.2 81.9
13.1 59 44.6 63.8
PVC SUVmax 0.014
8.0 40 56.0 89.5
8.0 105 47.0 68.8
Adenocarcinoma 70 51.0 76.7
SUVmax 0.019
5.2 25 56.4 95.8
5.2 45 46.3 66.5
PVC SUVmax 0.009
4.5 19 56.8 100
4.5 51 46.8 68.0
Other histologies 75 48.6 72.5
SUVmax 0.043
13.8 34 54.1 81.8
13.8 41 43.0 65.0
PVC SUVmax 0.038
14.8 35 54.2 81.8
14.8 40 44.0 64.8
FDG, fluorodeoxyglucose; SUVmax, maximum standardized uptake value; PVC
SUVmax, partial volume corrected SUVmax.
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DFS between the patients with a SUVmax less than or equal
to 13.1 (3-year DFS rate, 81.9%) and those with an SUVmax
more than 13.1 (3-year DFS rate, 63.8%; p  0.025). More-
over, there was a significant difference in DFS between the
patients with a PVC SUVmax less than or equal to 8.0 (3-year
DFS rate, 89.5%) and those with a PVC SUVmax more than
8.0 (3-year DSF rate, 68.8%; p  0.014; Table 3).
Subgroup analysis was performed in relation to tumor
histology. The patient population was subdivided at the cutoff
values of the SUVmax and PVC SUVmax, which were
previously calculated from ROC curves. The survival benefits
of the low SUVmax and PVC SUVmax group were also
significant for the patients with adenocarcinoma and other
histologies (Table 3, Figures 1B, C).
Univariate Survival Analysis in Relation to
Clinical Characteristics
Univariate analysis of the DFS was also performed in
the whole study patients according to stage, tumor size, the
presence of angiolymphatic invasion, age (dichotomized at
the median value), gender, smoking history, and weight loss
(Table 4). We conducted analyses for the tumor sizes of 3 and
5 cm as cutoff points and found tumor size to be a significant
prognostic factor for DFS (p  0.048). Weight loss (10%)
was also associated with DFS (p  0.041).
Multivariate Survival Analysis
SUVmax (model 1), PVC SUVmax (model 2), tumor
size, and weight loss were included in the multivariate anal-
ysis (Table 5). The SUVmax (hazard ratio 2.5, 95% CI:
1.2–5.1; p  0.012) remained significant in the multivariate
model 1. Furthermore, the PVC SUVmax (hazard ratio 2.6,
95% CI: 1.1–6.5; p  0.034) remained significant in the
multivariate model 2.
DICUSSION
Previous studies have shown that the pretherapeutic
18F-FDG uptake for the tumor can provide prognostic infor-
mation.3–8,12,13 Most studies have shown that patients with a
low SUV have significantly longer DFS or overall survival
than those with a high SUV.4,5,7,8,12,13 However, a recent
study revealed that SUVmax in patients with a new diagnosis
of advanced-stage NSCLC did not have a significant relation-
ship with survival.14 Moreover, the prognostic values of the
18F-FDG uptake in stage I NSCLC patients were not consis-
tent in the previous studies. For clinical stage I NSCLC, there
was no significant difference in the time to recurrence be-
FIGURE 1. A, Kaplan-Meier disease-free survival (DFS) curve
for all patients in the study (n  145). B, Kaplan-Meier DFS
curve for patients with adenocarcinoma (n  70). C, Kaplan-
Meier DFS curve for patients with other histologies (n  75).
TABLE 4. Univariate Analysis of the Disease-Free Survival
According to Clinical Characteristics
Factor
No.
Patients
Disease-Free Survival
Mean
Survival (mo)
3-yr
Survival (%)
Log-rank
p
Total group 145 50.1 74.5
Stage 0.882
IA 50 50.5 77.7
IB 95 49.6 72.8
Tumor size
(cm)
0.048
3.0 79 50.7 76.6
3.0  5.0 48 52.2 78.8
5.0 18 37.9 52.9
Angiolymphatic
invasion
0.164
No 137 50.8 76.0
Yes 8 38.0 50.0
Age 0.382
63 76 48.4 72.0
63 69 51.5 77.6
Sex 0.928
Male 109 49.0 72.6
Female 36 51.6 80.5
Smoking
history
0.806
Nonsmoker 50 51.6 77.8
Smoker 95 48.7 72.8
Weight loss 0.041
10% 131 51.4 77.3
10% 14 37.8 49.0
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tween the patients above and below the median SUV.15
However, high SUVmax on preoperative PET was an inde-
pendent predictor of relapse and death in resected pathologic
stage I NSCLC.16 For patients with pathologic stage I ade-
nocarcinoma, the SUV was found to be marginally correlated
with the frequency of tumor recurrence.17 In this study, the
SUVmax was an independent prognostic factor for DFS in
the whole patients with stage I NSCLC. Furthermore, sub-
group analysis revealed that the SUVmax was a prognostic
factor in patients with adenocarcinoma or other histologies.
Although the FDG uptake is dependent on tumor size,
the correction of partial volume effects has not been consid-
ered in previous studies.4,5,7,8,12,13 Partial volume effects re-
sult from the limited reconstructed resolution of a PET
scanner and artificially lower measured values of tumor
uptake, when tumor size is less than approximately two to
three times the reconstructed resolution of the PET im-
age.10,11 In the prospective study of all stages of NSCLC,
SUVmax was significantly associated with an increased risk
of death in univariate analysis, whereas PVC SUVmax was
only marginally associated.18 In this study, PVC SUVmax
and SUVmax were independent prognostic factors in the
multivariate analysis.
The features of NSCLC may be characterized by the
derangement of glucose metabolism. In the previous studies,
the FDG uptake of tumor was correlated with the overexpres-
sion of glucose transporter (GLUT)-1 and hexokinase in lung
cancer.19,20 However, GLUT1 was expressed in 100% of
squamous cell carcinomas but only in 58% of adenocarino-
mas.21 This discrepancy in the expression of GLUT1 could
explain the results of a higher 18F-FDG uptake for squamous
cell carcinoma than for adenocarcinoma in our and previous
studies.6–8 The cutoff values for the SUV to discriminate a
more or less favorable prognosis have ranged widely from 3.3
to 20 in the previous studies.3–8,15,17 In this study, the cutoff
value of the SUVmax for cancer recurrence was identified as
13.1 for the whole population. However, the cutoff value of
SUVmax for cancer recurrence was lower in patients with
adenocarcinoma than in patients with other histologies.
Therefore, caution is needed in the interpretation of the cutoff
value of SUVmax in relation to tumor histology. To be a
practical prognostic factor in routine practice, the standard-
ization of the methodology to be used to determine the
optimal threshold of SUVmax should be established among
all centers. Because SUV quantification, which depends on
fasting duration, plasma glucose level, the interval between
FDG injection and image acquisition, reconstruction, and
region of interest parameters, differs between different PET
scanners and different centers, the cutoff value for SUVmax
proposed by one study cannot be used by other centers.22,23
One limitation of our study was that performance status, an
important prognostic factor in lung cancer, was not included
in the analysis due to a significant number of missing values.
In conclusion, the intensity of FDG uptake for the
primary tumor was an independent prognostic factor for DFS,
even after correction for partial volume effects in the patients
with pathologic stage I NSCLC. However, the cutoff values
of SUVmax and PVC SUVmax to predict cancer recurrences
were lower in patients with adenocarcinoma than in those
with other histologies.
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